Targeting PIK3CA mutant breast cancer with the combination of PIK3CA-specific inhibitor, BYL719, and IGF1-R antibody, ganitumab

被引：0
|
作者：
Cao, Z. Alexander [1 ]
Pinzon-Ortiz, Maria [1 ]
Chen, Yan [1 ]
Li, Xiaoyan [1 ]
Beltran, Pedro J. [2 ]
Gansert, Jennifer [2 ]
Peters, Malte [3 ]
Schlegel, Robert [1 ]
Schumacher, Karl M. [3 ]
Huang, Alan [1 ]
机构：
[1] Novartis, Cambridge, MA USA
[2] Amgen Inc, Thousand Oaks, CA USA
[3] Novartis, Basel, Switzerland
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-3683
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3683
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Cancer-specific mutations in PIK3CA are oncogenic in vivo
    Bader, AG
    Kang, SY
    Vogt, PK
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (05) : 1475 - 1479
  • [32] Frequency and spectrum of PIK3CA somatic mutations in breast cancer
    Olga Martínez-Sáez
    Nuria Chic
    Tomás Pascual
    Barbara Adamo
    Maria Vidal
    Blanca González-Farré
    Esther Sanfeliu
    Francesco Schettini
    Benedetta Conte
    Fara Brasó-Maristany
    Adela Rodríguez
    Débora Martínez
    Patricia Galván
    Ana Belén Rodríguez
    Antonio Martinez
    Montserrat Muñoz
    Aleix Prat
    Breast Cancer Research, 22
  • [33] PIK3CA mutations in breast cancer are associated with poor outcome
    Li, SY
    Rong, MN
    Grieu, F
    Iacopetta, B
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 96 (01) : 91 - 95
  • [34] PIK3CA mutations in endocrine-resistant breast cancer
    Schagerholm, C.
    Robertson, S.
    Holm, B.
    Awier, H.
    Toosi, H.
    Sifakis, E.
    Hartman, J.
    VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S42 - S43
  • [35] Oncogenic PIK3CA mutations in lobular breast cancer progression
    Christgen, Matthias
    Noskowicz, Monika
    Schipper, Elisa
    Christgen, Henriette
    Heil, Charlotte
    Krech, Till
    Laenger, Florian
    Kreipe, Hans
    Lehmann, Ulrich
    GENES CHROMOSOMES & CANCER, 2013, 52 (01): : 69 - 80
  • [36] PIK3CA mutations in endocrine-resistant breast cancer
    Schagerholm, Caroline
    Robertson, Stephanie
    Toosi, Hosein
    Sifakis, Emmanouil G.
    Hartman, Johan
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [37] PIK3CA oncogenic mutations in neoadjuvant treatments for breast cancer
    Corso, Giovanni
    Veronesi, Paolo
    Intra, Mattia
    Sacchini, Virgilio
    Galimberti, Viviana
    BIOMARKERS IN MEDICINE, 2017, 11 (07) : 519 - 521
  • [38] PIK3CA Mutation Associates with Improved Outcome in Breast Cancer
    Kalinsky, Kevin
    Jacks, Lindsay M.
    Heguy, Adriana
    Patil, Sujata
    Drobnjak, Marija
    Bhanot, Umeshkumar K.
    Hedvat, Cyrus V.
    Traina, Tiffany A.
    Solit, David
    Gerald, William
    Moynahan, Mary Ellen
    CLINICAL CANCER RESEARCH, 2009, 15 (16) : 5049 - 5059
  • [39] PIK3CA mutations in breast cancer: A potential predictive marker
    Santarpia, M.
    Rosell, R.
    Margeli, M.
    Mesiti, M.
    Cavallari, V.
    Pitini, V.
    Cirauqui, B.
    Reguart, N.
    Barnadas, A.
    Taron, M.
    Altavilla, G.
    ANNALS OF ONCOLOGY, 2006, 17 : VII146 - VII147
  • [40] Prognosis of women with early breast cancer and PIK3CA mutations
    Di Cosimo, Serena
    Bianchi, Giulia Valeria
    Bregni, Giacomo
    de Braud, Filippo
    BREAST, 2015, 24 (03): : 283 - 284
12345